Jump to content

Boehringer Ingelheim

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 86.165.94.223 (talk) at 15:04, 18 January 2014 (→‎History). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

C. H. Boehringer Sohn AG & Co. KG
Company typePrivate
IndustryPharmaceuticals
FoundedGermany (1885)
HeadquartersBinger Str. 173, 55216 Ingelheim Germany
Key people
Andreas Barner, Chairman of the board
Hubertus von Baumbach, board member
Wolfgang Baiker, board member
Allan Hillgrove, board member
Joachim Hasenmaier, board member
ProductsHuman Pharmaceuticals and Animal Health
RevenueIncrease€14.7 billion EUR (2012)
Increase€1.85 billion EUR (2012)
Number of employees
46,228 (2012)
Websitehttp://www.boehringer-ingelheim.com

C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 140 affiliates and more than 46,000 employees. The company's key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease, cerebrovascular disease, oncology, diabetes and hepatitis. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.[1]

In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.[2]

Activities

Boehringer Ingelheim works in human pharmaceuticals, animal health and biopharmaceuticals.[citation needed] The group consists of 140 affiliated companies with more than 46,000 employees in all continents. Research and development (R&D) facilities were in five sites and 20 production plants in 13 countries. The research and development (R&D) facilities are located in Biberach/Germany, Ridgefield (Connecticut)/US, Vienna/Austria, Kobe/Japan and Milan/Italy. Over 7,000 employees work for the Boehringer Ingelheim in research and development.

History

History

  • 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on August 1.[citation needed]
  • 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
  • 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.[citation needed]
  • 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
  • 1895: Lactic acid is produced on an industrial scale, and is successful commercially.
  • 1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
  • 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.[citation needed]
  • 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
  • 1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted at the Nuremberg Trials.
  • 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
  • 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
  • 1985: The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988.
  • 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.[citation needed]
  • 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
  • 2010: The company celebrates its 125th anniversary.

Collaborative research

Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[3][4] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[5]

Operational/development sites

Boehringer Ingelheim is a globally operating company, with 140 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.[citation needed]

Closure of drug manufacturing plant

In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down[6] after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid',[7] later found to be urine.[7] The company invested US$300 million to upgrade the drug manufacturing plant, and limited production resumed in October 2012.[7] However, on October 3, 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production".[8]

Awards

In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.[9]

In Germany, Brazil, the Netherlands, and the United Kingdom, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the British newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disabled Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.[citation needed]

Key product lines

Prescription Medicine:

Consumer Health Care:

  • Antistax(red vine leaf extract)
  • Bisolvon (bromhexine)
  • Buscopan , Buscapina (hyoscine butylbromide)
  • Dulcolax (bisacodyl, sodium, picosulphate)
  • Mucoangin (ambroxol)
  • Mucosolvan (ambroxol)
  • Pharmaton (standardised ginseng extract, vitamins, minerals, trace elements)
  • Silomat DMP (dextrometorphan)
  • Thomapyrin (acetylsalicylic acid, paracetamol, caffeine)

Animal Health:

Product Pipeline

Boehringer Ingelheim's product pipeline[10] targets lung disease, cancer, and Hepatitis C

Drug Name Description Potential Indication Testing Phase
Olodaterol Long-acting beta-agonist Chronic obstructive pulmonary disease (COPD) submitted for approval
Tiotropium Long Acting Muscarinic Antagonist Cystic fibrosis (CF) / Asthma. Already approved for Chronic obstructive pulmonary disease (COPD) submitted for approval
Nintedanib Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR Idiopathic pulmonary fibrosis (IPF) / Non-small cell lung cancer (NSCLC) / Ovarian cancer Phase III
Afatinib irreversible ErbB Family blocker Breast cancer/Head and neck cancer. Already approved for Non-small cell lung cancer (NSCLC) Phase III
Volasertib PLK-1 antagonist Various cancer types Phase III
Deleobuvir (formerly BI 207127) NS5B RNA-dependent polymerase inhibitor Hepatitis C Phase III
Faldaprevir (formerly BI 201335) NS3/4A protease inhibitor Hepatitis C Phase III
Empagliflozin SGLT-2-inhibitor Diabetes mellitus type II Phase III

See also

References

  1. ^ "Boehringer Ingelheim Logo: Design and History". FamousLogos.us. Retrieved 2011-08-18.
  2. ^ "Boehringer Ingelheim pays $95 million to settle whistleblower case" Phillips & Cohen Press Release, October 25, 2012.
  3. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1007/978-1-60327-048-9_11, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1007/978-1-60327-048-9_11 instead.
  4. ^ "InnoMed PredTox Member Organizations". Retrieved 2008-08-25.
  5. ^ Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.
  6. ^ "Ben Venue Laboratories – Voluntary Shutdown". US Food and Drug Adminstration. Web Page Last Updated: 11/30/2011. Retrieved 18 October 2012. {{cite web}}: Check date values in: |date= (help)
  7. ^ a b c THOMAS, KATIE (18 October 2012). "Lapses at Big Drug Factories Add to Shortages and Danger". New York Times. p. 10/18/12 N.Y. Times A1. Retrieved 18 October 2012.
  8. ^ "Ben Venue Laboratories, Inc to Cease Production". Retrieved 4 October 2013.
  9. ^ Gwynne, Peter (October 20, 2006), "TOP EMPLOYER SURVEY: It All Starts with Science",Science. Retrieved August 26, 2007.
  10. ^ "Boehringer Ingelheim Product Pipeline". Retrieved 2013-09-12.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Boehringer_Ingelheim&oldid=591277731"